Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Serdar Sel is active.

Publication


Featured researches published by Serdar Sel.


Journal of Immunology | 2007

Immunomodulatory Effects of Viral TLR Ligands on Experimental Asthma Depend on the Additive Effects of IL-12 and IL-10

Serdar Sel; Michael Wegmann; Sarper Sel; Stefan Bauer; Holger Garn; Gottfried Alber; Harald Renz

Based on epidemiological data, the hygiene hypothesis associates poor hygienic living conditions during childhood with a lower risk for the development of allergic diseases such as bronchial asthma. The role of viral infections, and especially of viral TLR ligands, within this context remains to be clarified. Viral TLR ligands involve dsRNA and ssRNA which are recognized by TLR-3 or TLR-7, respectively. In this study, we evaluated the impact of TLR-3 or TLR-7 activation on experimental asthma in mice. Systemic application of the synthetic TLR-3 or TLR-7 ligands polycytidylic-polyinosinic acid (p(I:C)) or R-848, respectively, during the sensitization phase prevented the production of OVA-specific IgE and IgG1 Abs and subsequently abolished all features of experimental asthma including airway hyperresponsiveness and allergic airway inflammation. Furthermore, administration of p(I:C) or R-848 to animals with already established primary allergic responses revealed a markedly reduced secondary response following allergen aerosol rechallenges. In contrast to wild-type animals, application of p(I:C) or R-848 to IL-12p35−/− mice had no effect on airway inflammation, goblet cell hyperplasia, and airway hyperresponsiveness. However, in the absence of IL-12, the numbers of eosinophils and lymphocytes in bronchoalveolar lavage fluids were still significantly reduced. These partial effects could also be abolished by neutralizing anti-IL-10 Abs in IL-12p35−/− mice. These data indicate that TLR-3 or TLR-7 activation by viral TLR ligands has both preventive as well as suppressive effects on experimental asthma which is mediated by the additive effects of IL-12 and IL-10.


The Journal of Allergy and Clinical Immunology | 2008

Effective prevention and therapy of experimental allergic asthma using a GATA-3–specific DNAzyme

Serdar Sel; Michael Wegmann; Tanja Dicke; Sarper Sel; Wolfgang Henke; Ali Oender Yildirim; Harald Renz; Holger Garn

BACKGROUND Allergic bronchial asthma is a chronic inflammatory disease of the airways. The transcription factor GATA-3 was shown to play an important role in TH2 cell activation, but also in the regulation of other cell types involved in bronchial asthma including mast cells, eosinophils, and epithelial cells. DNAzymes represent a new class of antisense molecules that combines the specificity of DNA base pairing with an inherent RNA-cleaving enzymatic activity. OBJECTIVE To develop a GATA-3 mRNA-specific DNAzyme and analyze its allergy-preventing activity in murine models of experimental allergic asthma. METHODS The most active DNAzyme (termed gd21) was selected by in vitro cleavage assays. Allergic airway inflammation was assessed by inflammatory cell and cytokine analysis within bronchoalveolar lavage. Lung histology, including goblet cell hyperplasia and lung function, was analyzed using head-out body-plethysmography. RESULTS Intranasal administration of gd21 prevented airway inflammation and mucus production and inhibited development of airway hyperresponsiveness to methacholine in models of acute allergic airway inflammation. Similar effects were also detected in a model of chronic experimental asthma. Interestingly, gd21 was at least as effective as other antisense molecules, and off-target effects were not detected. Further experiments indicated that pulmonary surfactant may facilitate the cellular uptake of gd21 by acting as an endogenous transfectant. CONCLUSION These results indicate that topical application of the GATA-3-specific DNAzyme is a promising novel approach for the treatment of allergic bronchial asthma.


The FASEB Journal | 2007

Anti-ulcer treatment during pregnancy induces food allergy in mouse mothers and a Th2-bias in their offspring

Isabella Schöll; Ute Ackermann; Cevdet Ozdemir; Nicole Blümer; Tanja Dicke; Serdar Sel; Sarper Sel; Michael Wegmann; Krisztina Szalai; Regina Knittelfelder; Eva Untersmayr; Otto Scheiner; Holger Garn; Erika Jensen-Jarolim; Harald Renz

The treatment of dyspeptic disorders with anti‐acids leads to an increased risk of sensitization against food allergens. As these drugs are taken by 30–50% of pregnant women due to reflux and heartburn, we aimed here to investigate the impact of maternal therapy with anti‐acids on the immune response in the offspring in a murine model. Codfish extract as model allergen was fed with or without sucralfate, an anti‐acid drug, to pregnant BALB/c mice during pregnancy and lactation. These mothers developed a codfish‐specific allergic response shown as high IgG1 and IgE antibody levels and positive skin tests. In the next step we analyzed whether this maternal sensi‐tization impacts a subsequent sensitization in the offspring. Indeed, in stimulated splenocytes of these off‐spring we found a relative Th2‐dominance, because the Thl‐ and T‐regulatory cytokines were significantly sup‐pressed. Our data provide evidence that the anti‐acid drug sucralfate supports sensitization against food in pregnant mice and favors a Th2‐milieu in their offspring. From these results we propose that anti‐acid treatment during pregnancy could be responsible for the increasing number of sensitizations against food allergens in young infants.—Schöll, I., Ackermann, U., Özdemir, C., Blümer, N., Dicke, T., Sel, S., Sel, S., Wegmann, M., Szalai, K., Knittelfelder, R., Untersmayr, E., Scheiner, O., Garn, H., Jensen‐Jarolim, E., Renz, H. Anti‐ulcer treatment during pregnancy induces food allergy in mouse mothers and a Th2‐bias in their offspring. FASEB J. 21, 1264–1270 (2007)


Journal of Neuroimmunology | 2005

A role for brain-derived neurotrophic factor in B cell development

Berit Schuhmann; Alexander Dietrich; Serdar Sel; Christian Hahn; Martin Klingenspor; Marek Lommatzsch; Thomas Gudermann; Armin Braun; Harald Renz; Wolfgang Andreas Nockher

In the present study, we demonstrated a significant reduction of B lymphocytes in the blood, spleen and bone marrow of BDNF deficient mice. The observed developmental block in bone marrow B cell development was linked specifically to the Pre-BII stage. B lymphocytes express the BDNF receptors p75NTR and TrkB(gp95), while no BDNF expression was found. However, a strong BDNF expression was demonstrated in bone marrow stromal cells. An increase of intracellular free calcium [Ca2+]i in B lymphocytes after BDNF application confirms a direct responsiveness of B lymphocytes to BDNF. In conclusion, these results suggest a role of BDNF for normal B lymphocyte development through paracrine effects in the bone marrow.


American Journal of Respiratory Cell and Molecular Biology | 2007

Effects of a Low-Molecular-Weight CCR-3 Antagonist on Chronic Experimental Asthma

Michael Wegmann; Rolf Göggel; Sarper Sel; Serdar Sel; Klaus J. Erb; Frank Kalkbrenner; Harald Renz; Holger Garn


Chemical immunology and allergy | 2006

The Immunological Basis of the Hygiene Hypothesis

Harald Renz; Nicole Blümer; Simona Virna; Serdar Sel; Holger Garn


in Vivo | 2008

Analysis of Cytokine Levels in Human Lymphangiomas

Susanne Wiegand; Behfar Eivazi; Serdar Sel; Harald Renz; Jochen A. Werner; Benedikt J. Folz


Current Pharmaceutical Design | 2006

Treatment of allergic asthma by targeting transcription factors using nucleic-acid based technologies.

Serdar Sel; Wolfgang Henke; Alexander Dietrich; Udo Herz; Harald Renz


Archive | 2004

Method for the production of a cell and/or tissue and/or disease phase specific medicament

Serdar Sel; Harald Renz


Archive | 2011

Method for producing a cell and/or tissue and/or disease phase specific medicament

Serdar Sel; Harald Renz

Collaboration


Dive into the Serdar Sel's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Isabella Schöll

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge